Chen Muhua, Bie Lei
Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Department of Thoracic Surgery, Wuhan No.1 Hospital, Wuhan, 430030, Hubei, China.
Cancer Cell Int. 2025 Apr 17;25(1):152. doi: 10.1186/s12935-025-03745-7.
Intratumoral microbiota has been found to be a crucial component of hepatocellular carcinoma (HCC). Due to insufficient recognition, technical limitations, and low biomass of intratumoral microbiota, it is poorly understood. Intratumoral microbiota exhibit significant diversity in HCC tissues. It is involved in the development of HCC through several mechanisms, such as remodeling the immunosuppressive microenvironment, metabolic reprogramming, and genetic alterations. Moreover, intratumoral microbiota is associated with the metastasis of HCC cells. Herein, we reviewed the history of intratumoral microbiota, applied biotechnology to depict the signatures of intratumoral microbiota, investigated the potential sources of intratumoral microbiota, and assessed their functions, mechanisms, and heterogeneity. Furthermore, in this review, we summarized the development of therapeutics that can be used in the treatment of HCC and proposed future perspectives for research in this field.
肿瘤内微生物群已被发现是肝细胞癌（HCC）的一个关键组成部分。由于对其认识不足、技术限制以及肿瘤内微生物群生物量较低，人们对它了解甚少。肿瘤内微生物群在肝癌组织中表现出显著的多样性。它通过多种机制参与肝癌的发生发展，如重塑免疫抑制微环境、代谢重编程和基因改变。此外，肿瘤内微生物群与肝癌细胞的转移有关。在此，我们回顾了肿瘤内微生物群的研究历史，应用生物技术描绘肿瘤内微生物群的特征，研究肿瘤内微生物群的潜在来源，并评估它们的功能、机制和异质性。此外，在本综述中，我们总结了可用于治疗肝癌的治疗方法的进展，并提出了该领域未来的研究展望。
